UCB BIOPHARMA

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2025-12-23",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "stage": null,
  "notary": {
    "name": "Philip Van Nevel",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2025-06-11",
    "filing_date": "2025-06-03",
    "act_kind_objet": "All\u00E9e de la Recherche 60 - 1070 Bruxelles (Anderlecht)"
  },
  "decision": {
    "body": "raad_van_bestuur",
    "act_date": "2025-05-26",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0543.573.053",
        "name": "UCB Biopharma",
        "role": "other",
        "address": "All\u00E9e de la Recherche 60 - 1070 Bruxelles (Anderlecht)",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "2:8 \u00A74"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": null,
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "Aucun transfert de patrimoine n\u0027est effectu\u00E9. L\u0027acte concerne la communication du d\u00E9p\u00F4t des r\u00E9solutions \u00E9crites des administrateurs, qui constatent que toutes les actions de la soci\u00E9t\u00E9 sont d\u00E9tenues par un seul actionnaire.",
    "equity_transferred_eur": null,
    "accounting_effective_date": null
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB Biopharma",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 Responsabilit\u00E9 Limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Philip Van Nevel",
    "org_rep_person_name": null
  },
  "summary_narrative": "Les administrateurs de UCB Biopharma, soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e, ont adopt\u00E9 des r\u00E9solutions \u00E9crites unanimes le 26 mai 2025, confirmant que toutes les actions de la soci\u00E9t\u00E9 sont d\u00E9tenues par un seul actionnaire. Ces r\u00E9solutions ont \u00E9t\u00E9 d\u00E9pos\u00E9es au greffe du tribunal de l\u0027entreprise francophone de Bruxelles le 3 juin 2025, conform\u00E9ment \u00E0 l\u0027article 2:8 \u00A74 du Code des soci\u00E9t\u00E9s et associations.",
  "co_filed_documents": [
    "R\u00E9solutions \u00E9crites des administrateurs de la soci\u00E9t\u00E9 du 26 mai 2025"
  ],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": "statutes"
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2025-05-01",
    "legal_form_change": false
  },
  "bedrijfsrevisor": {
    "quote": "Le commissaire, la soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e \u00AB Forvis Mazars R\u00E9viseurs d\u0027Entreprises \u00BB, repr\u00E9sent\u00E9e par Monsieur S\u00E9bastien Schueremans, r\u00E9viseur d\u2019entreprises, a \u00E9tabli un rapport \u00E9crit sur le projet de scission partielle en application de l\u2019article 12:62 du Code des soci\u00E9t\u00E9s et des associations.",
    "firm_kbo": null,
    "firm_name": "Forvis Mazars R\u00E9viseurs d\u0027Entreprises",
    "ibr_number": null,
    "individual_name": "S\u00E9bastien Schueremans"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "stage": null,
  "notary": {
    "name": "Samuel Wynant",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2025-03-18",
    "filing_date": "2025-03-14",
    "act_kind_objet": "DIVERS"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2025-03-14",
    "unanimous": true
  },
  "conversion": null,
  "detected_kind": "other",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0543.573.053",
        "name": "UCB BIOPHARMA",
        "role": "demerged",
        "address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": null
      },
      {
        "kbo": "1017.533.562",
        "name": "UCB DEVELOPED BRANDS",
        "role": "recipient",
        "address": "All\u00E9e de la Recherche 60, 1070 Anderlecht",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": null
      }
    ],
    "exchange_ratio": 1.0,
    "legal_articles": [
      "12:8",
      "12:4",
      "12:59",
      "12:67",
      "12:69"
    ],
    "is_cross_border": false,
    "is_silent_merger": false,
    "balance_basis_date": "2024-12-31",
    "exchange_ratio_text": "1 action pour 1 action",
    "new_shares_issued_n": 32383629,
    "real_estate_included": false,
    "patrimony_description": "Le patrimoine transf\u00E9r\u00E9 comprend les droits de propri\u00E9t\u00E9 intellectuelle, les frais de recherche et d\u00E9veloppement (R\u0026D), les cr\u00E9dits d\u0027imp\u00F4t R\u0026D, ainsi que les contrats de travail des employ\u00E9s transf\u00E9r\u00E9s li\u00E9s au portefeuille mature. Les passifs associ\u00E9s aux employ\u00E9s transf\u00E9r\u00E9s sont \u00E9galement transf\u00E9r\u00E9s.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2025-05-01"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "detected_kind_raw": "parti\u00EBle splitsing",
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Freshfields LLP",
    "person_name": null,
    "org_rep_person_name": "Dennis Beyers, Aur\u00E9lie Saint-Amand, Valentijn Peeters, Dominique Lecocq, Deborah Janssens, Elliott Foss\u00E9prez, Guillaume Nelis, Els De Troyer, Philip Van Nevel, Matthieu Derynck, Anne-Catherine Guiot"
  },
  "summary_narrative": "Le projet de scission partielle de UCB Biopharma pr\u00E9voit le transfert des actifs et passifs li\u00E9s \u00E0 son portefeuille de m\u00E9dicaments matures, notamment Cimzia\u00AE, Keppra\u00AE et Briviact\u00AE, \u00E0 UCB Developed Brands. Cette op\u00E9ration, approuv\u00E9e par les conseils d\u0027administration des deux soci\u00E9t\u00E9s, sera soumise \u00E0 l\u0027approbation des assembl\u00E9es g\u00E9n\u00E9rales extraordinaires pr\u00E9vues pour le 28 avril 2025. \u00C0 compter du 1er mai 2025, UCB Developed Brands \u00E9mettra une action ordinaire pour chaque action existante de UCB Biopharma, sans contrepartie en esp\u00E8ces.",
  "co_filed_documents": [],
  "detected_real_type": "other",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2024-12-10",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Patel, Dhavalkumar",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2024-07-01",
      "evidence_quote": "d\u0027accepter la d\u00E9mission de M. Dhavalkumar (connu sous le nom \u003C Dhaval \u00BB) Patel, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), en qualit\u00E9 d\u0027administrateur de la soci\u00E9t\u00E9 avec effet au 1 juillet 2024."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Henry, Alistair",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2024-06-24",
      "evidence_quote": "de nommer M. Alistair Henry, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), avec effet imm\u00E9diat, en qualit\u00E9 de nouvel administrateur pour une dur\u00E9e intermin\u00E9e."
    },
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Schueremans, S\u00E9bastien",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "Mazars Bedrijfsrevisoren - R\u00E9viseurs d\u0027Entreprises BV/SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2024-06-24",
      "evidence_quote": "de nommer Mazars Bedrijfsrevisoren - R\u00E9viseurs d\u0027Entreprises BV/SRL, commissaire aux comptes, dont le mandat expire \u00E0 l\u0027issue de l\u0027assembl\u00E9e g\u00E9n\u00E9rale des actionnaires de 2024 pour une dur\u00E9e de 3 ans, jusqu\u0027\u00E0 et y compris l\u0027assembl\u00E9e g\u00E9n\u00E9rale annuelle de 2027 (convoqu\u00E9e pour statuer sur les comptes a"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "William Silbey",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2023-03-31",
      "evidence_quote": "Les Actionnaires, \u00E0 l\u0027unanimit\u00E9, actent la d\u00E9mission de William Silbey, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), en qualit\u00E9 d\u0027administrateur avec effet au 31 mars 2023."
    },
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Denelle J. Waynick Johnson",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2023-04-01",
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 5:85 du Code des soci\u00E9t\u00E9s et associations, les Actionnaires d\u00E9cident \u00E0 l\u0027unanimit\u00E9 de ratifier la nomination de Denelle J. Waynick Johnson, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), en qualit\u00E9 d\u0027administrateur de la Soci\u00E9t\u00E9 avec eff"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 819225268.29,
      "currency": "EUR",
      "after_eur": 2794969032.02,
      "delta_eur": 819225268.29,
      "before_eur": null,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2022-07-15",
      "evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019accepter un premier apport \u00E0 concurrence d\u2019un montant de 819.225.268,29 EUR, r\u00E9mun\u00E9r\u00E9 par l\u2019\u00E9mission de 16.968.535 nouvelles actions... Ces actions nouvelles seront attribu\u00E9es, enti\u00E8rement lib\u00E9r\u00E9es, \u00E0 la soci\u00E9t\u00E9 anonyme UCB PHARMA, en r\u00E9mun\u00E9ration de l\u0027apport en nature par cette derni\u00E8re de la note intra-groupe d\u2019un montant total de 819.225.268,29 EUR au 15 juillet 2022",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_increase",
      "amount": 180774731.71,
      "currency": "EUR",
      "after_eur": 2794969032.02,
      "delta_eur": 180774731.71,
      "before_eur": null,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2022-07-15",
      "evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019accepter un second apport \u00E0 concurrence d\u2019un montant de 180.774.731,71 EUR, r\u00E9mun\u00E9r\u00E9 par l\u2019\u00E9mission de 3.744.370 nouvelles actions... Ces actions nouvelles seront souscrites pour le montant total de 180.774.731,71 EUR et int\u00E9gralement lib\u00E9r\u00E9es en esp\u00E8ces lors de la souscription.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "BV"
  }
}

{
  "events": [
    {
      "kind": "commissaris_out",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Romain Seffer",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "PwC Reviseurs d\u0027entreprises SRL",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2021-04-28",
      "evidence_quote": "d\u0027acter la d\u00E9mission de PwC Reviseurs d\u0027entreprises SRL, ayant son si\u00E8ge social \u00E0 Woluwedal 18, 1932 Sint-Stevens-Woluwe, repr\u00E9sent\u00E9e par Romain Seffer, en qualit\u00E9 de commissaire de la Soci\u00E9t\u00E9 dont le mandat prendra fin au moment de l\u0027entr\u00E9e en vigueur des pr\u00E9sentes d\u00E9cisions unanimes par \u00E9crit;"
    },
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Anton Nuttens",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": "0428837889",
        "name": "Mazars R\u00E9viseurs d\u0027Entreprises SC",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "effective_date": "2021-04-28",
      "evidence_quote": "de nommer Mazars R\u00E9viseurs d\u0027Entreprises SC, ayant son si\u00E8ge social \u00E0 Avenue du Boulevard 21, bo\u00EEte 8, 1210 Saint-Josse-ten-Noode (Bruxelles) et portant le num\u00E9rp d\u0027entreprise 0428.837.889, comme nouveau commissaire pour une dur\u00E9e de 3 ans, jusqu\u0027\u00E0 et y compris l\u0027assembl\u00E9e g\u00E9n\u00E9rale appel\u00E9e \u00E0 statuer"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Damien HISETTE",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2021-05-25",
    "filing_date": "2021-05-20",
    "act_kind_objet": "DIVERS"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2021-05-19",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0543.573.053",
        "name": "UCB BIOPHARMA",
        "role": "acquiring",
        "address": "All\u00E9e de la Recherche 60, 1070 Bruxelles (Anderlecht)",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0735.503.488",
        "name": "HANDL THERAPEUTICS",
        "role": "absorbed",
        "address": "Gaston Geenslaan 1, 3001 Leuven (Heverlee)",
        "is_foreign": false,
        "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:50",
      "12:51",
      "12:52"
    ],
    "is_cross_border": false,
    "is_silent_merger": true,
    "balance_basis_date": "2020-12-31",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "L\u0027ensemble du patrimoine de la Soci\u00E9t\u00E9 Absorb\u00E9e, y compris tous ses actifs, passifs, droits et obligations, sera transf\u00E9r\u00E9 de plein droit \u00E0 la Soci\u00E9t\u00E9 Absorbante. L\u0027op\u00E9ration s\u0027inscrit dans le cadre de l\u0027int\u00E9gration strat\u00E9gique du groupe UCB, notamment en mati\u00E8re de propri\u00E9t\u00E9 intellectuelle.",
    "equity_transferred_eur": 104715.0,
    "accounting_effective_date": "2021-01-01"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "Soci\u00E9t\u00E9 \u00E0 responsabilit\u00E9 limit\u00E9e"
  },
  "publication_proxy": {
    "kind": "org",
    "org_kbo": null,
    "org_name": "Damien HISETTE, notaire",
    "person_name": null,
    "org_rep_person_name": null
  },
  "summary_narrative": "Le projet de fusion par absorption de HANDL THERAPEUTICS par UCB BIOPHARMA a \u00E9t\u00E9 \u00E9tabli le 19 mai 2021. La Soci\u00E9t\u00E9 Absorbante, d\u00E9tenant d\u00E9j\u00E0 100 % des actions de la Soci\u00E9t\u00E9 Absorb\u00E9e, propose une fusion assimil\u00E9e \u00E0 une fusion par absorption conform\u00E9ment \u00E0 l\u0027article 12:50 du Code des soci\u00E9t\u00E9s et des associations. Aucune action n\u0027est \u00E9mise ni r\u00E9mun\u00E9ration accord\u00E9e. L\u0027effet comptable de la fusion est r\u00E9troactif au 1er janvier 2021.",
  "co_filed_documents": [
    "le projet de fusion"
  ],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Sandrine DUFOUR",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2019-09-28",
      "evidence_quote": "Les actionnaires, conform\u00E9ment \u00E0 l\u0027article 5:85 du Code des soci\u00E9t\u00E9s et des associations, d\u00E9cident \u00E0 l\u0027unanimit\u00E9 de nommer, avec effet imm\u00E9diat, Sandrine DUFOUR, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), en qualit\u00E9 d\u0027administrateur additionnel de la Soci\u00E9t\u00E9"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Detlef Thielgen",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2020-04-10",
      "evidence_quote": "Le Conseil acte la d\u00E9mission de Monsieur Detlef Thielgen en qualit\u00E9 d\u0027Administrateur avec effet au 10 avril 2020."
    },
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Romain Seffer",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SRL PWC Reviseurs d\u0027Entreprises",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "de nommer la SRL PWC Reviseurs d\u0027Entreprises, ayant son si\u00E8ge social \u00E0 1932 Sint-Stevens-Woluwe, Woluwedal 18, comme commissaire pour un terme de trois ans. Le repr\u00E9sentant permanent de la SRL PwC Reviseurs d\u0027Entreprises sera Romain Seffer, r\u00E9viseur d\u0027entreprises."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SRL"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2019-12-02",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  },
  "signature_regime": "solo",
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "William SILBEY",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2019-03-22",
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 268 $2 du Code des Soci\u00E9t\u00E9s, d\u00E9cident \u00E0 l\u0027uriarimit\u00E9 de nommer, avec effet: imm\u00E9diat, William (\u003C connu sous de nom de Bill \u00BB) SILBEY, avec adresse professionelle All\u00E9e de la Recherche, 60 \u00E0 1070 Anderlecht (Bruxelles), er qualit\u00E9 de g\u00E9rant additiorirel de la Soci\u00E9t\u00E9."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 33044986.43,
      "currency": "EUR",
      "after_eur": 1383611620.86,
      "delta_eur": 33044986.43,
      "before_eur": 1350566634.43,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2019-04-30",
      "evidence_quote": "L\u2019assembl\u00E9e d\u00E9cide d\u2019augmenter le capital social \u00E0 concurrence de 33.044.986,43 EUR pour le porter de 1.350.566.634,43 EUR \u00E0 1.383.611.620,86 EUR par l\u2019\u00E9mission de 277.272 nouvelles parts sociales... Ces parts sociales nouvelles seront attribu\u00E9es, enti\u00E8rement lib\u00E9r\u00E9es, \u00E0 la soci\u00E9t\u00E9 anonyme UCB Pharma, en r\u00E9mun\u00E9ration de l\u0027apport par cette derni\u00E8re d\u0027une partie du pr\u00EAt... pour un montant de 305.116.347,97 EUR",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_increase",
      "amount": 7293036.8,
      "currency": "EUR",
      "after_eur": 1390904657.66,
      "delta_eur": 7293036.8,
      "before_eur": 1383611620.86,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2019-04-30",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de 7.293.036,80 EUR pour le porter de 1.383.611.620,86 EUR \u00E0 1.390.904.657,66 EUR par l\u2019\u00E9mission de 61.194 nouvelles parts sociales... int\u00E9gralement lib\u00E9r\u00E9es en esp\u00E8ces lors de la souscription.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Anna S. Richo",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2018-12-13",
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 536 du Code des soci\u00E9t\u00E9s, les Actionnaires, \u00E0 l\u0027unanimit\u00E9, acceptent la d\u00E9mission de Anna S. Richo, All\u00E9e de la Recherche, 60 \u00E0 1070 Bruxelles, en qualit\u00E9 de G\u00E9rant, avec effet au 13 d\u00E9cembre 2018."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 1662293910,
      "currency": "EUR",
      "after_eur": 3647358235.46,
      "delta_eur": 1662293910.0,
      "before_eur": 1985064325.46,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2018-11-30",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de 1.662.293.910 EUR pour le porter de 1.985.064.325,46 EUR \u00E0 3.647.358.235,46 EUR par incorporation d\u2019une m\u00EAme somme pr\u00E9lev\u00E9e sur les primes d\u2019\u00E9mission",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_decrease",
      "amount": 2397392818.98,
      "currency": "EUR",
      "after_eur": 1249965416.48,
      "delta_eur": -2397392818.98,
      "before_eur": 3647358235.46,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2018-11-30",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide de r\u00E9duire le capital social \u00E0 concurrence de 2.397.392.818,98 EUR pour le ramener de 3.647.358.235,46 EUR \u00E0 1.249.965.416,48 EUR par amortissement \u00E0 due concurrence des pertes figurant aux comptes annuels arr\u00EAt\u00E9s au 31 d\u00E9cembre 2017",
      "contribution_type": "in_kind"
    },
    {
      "kind": "capital_increase",
      "amount": 100601217.95,
      "currency": "EUR",
      "after_eur": 1350566634.43,
      "delta_eur": 100601217.95,
      "before_eur": 1249965416.48,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2018-11-30",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de 100.601.217,95 EUR pour le porter de 1.249.965.416,48 EUR \u00E0 1.350.566.634,43 EUR par l\u2019\u00E9mission de 844.119 nouvelles parts sociales... int\u00E9gralement lib\u00E9r\u00E9es en esp\u00E8ces lors de la souscription.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "zaakvoerder",
      "person": {
        "rrn": null,
        "name": "Fabrice Enderlin",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2017-12-12",
      "evidence_quote": "1.d\u0027accepter la d\u00E9mission de Monsieur Fabrice Enderlin en qualit\u00E9 de G\u00E9rant de la soci\u00E9t\u00E9 avec effet au 12 d\u00E9cembre 2017;"
    },
    {
      "kind": "director_out",
      "role": "zaakvoerder",
      "person": {
        "rrn": null,
        "name": "Ismail Kola",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2017-12-12",
      "evidence_quote": "2.de terminer le mandat de Monsieur Ismail Kola en qualit\u00E9 de G\u00E9rant de la soci\u00E9t\u00E9 avec effet au 12 d\u00E9cembre 2017;"
    },
    {
      "kind": "director_in",
      "role": "zaakvoerder",
      "person": {
        "rrn": null,
        "name": "Jean-Luc Fleurial",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2017-12-12",
      "evidence_quote": "3.d\u0027approuver la nomination de Monsieur Jean-Luc Fleurial ... en qualit\u00E9 de G\u00E9rants de la soci\u00E9t\u00E9 avec effet \u00E0 cette m\u00EAme date et pour un terme ind\u00E9termin\u00E9."
    },
    {
      "kind": "director_in",
      "role": "zaakvoerder",
      "person": {
        "rrn": null,
        "name": "Dhavalkumar Patel",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2017-12-12",
      "evidence_quote": "3.d\u0027approuver la nomination de ... Monsieur Dhavalkumar Patel (connu sous le nom de \u003C\u003C Dhaval \u00BB) ... en qualit\u00E9 de G\u00E9rants de la soci\u00E9t\u00E9 avec effet \u00E0 cette m\u00EAme date et pour un terme ind\u00E9termin\u00E9."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "commissaris_in",
      "role": "commissaris",
      "person": {
        "rrn": null,
        "name": "Romain Seffer",
        "address": null,
        "birth_date": null
      },
      "via_org": {
        "kbo": null,
        "name": "SCCRL PwC Reviseurs d\u0027Entreprises",
        "address": null,
        "country": null,
        "legal_form": null
      },
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 268 $2 du Code des Soci\u00E9t\u00E9s, les actionnaires, \u00E0 l\u0027unanimit\u00E9, d\u00E9cident de nommer la SCCRL PwC Reviseurs d\u0027Entreprises, ayant son si\u00E8ge social \u00E0 1932 Sint-Stevens-Woluwe, Woluwedal 18, comme commissaire pour un terme de trois ans. Le repr\u00E9sentant permanent de la SCCRL PwC Rev"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Mark McDade",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2016-12-31",
      "evidence_quote": "Mark McDade prenant sa retraite au sein du Groupe UCB \u00E0 fin d\u00E9cembre, le Conseil est inform\u00E9 qu\u0027il va \u00E9galement d\u00E9missionner en qualit\u00E9 de G\u00E9rant avec effet au 31 d\u00E9cembre 2016. Le Conseil accepte la d\u00E9mission de Mark McDade en qualit\u00E9 de g\u00E9rant de la soci\u00E9t\u00E9 avec effet au 31 d\u00E9cembre 2016 \u00E0 23 h 59"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "date": "2016-01-01",
      "kind": "fusie_overgenomen",
      "liquidators": [],
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide de la fusion de la soci\u00E9t\u00E9 avec la soci\u00E9t\u00E9 priv\u00E9e limit\u00E9e par actions de droit irlandais UCB BIOPHARMA IRELAND LIMITED ... par voie de transfert, par suite d\u0027une dissolution sans liquidation de cette derni\u00E8re, de l\u0027int\u00E9gralit\u00E9 de son patrimoine, activement et passivement, au profit de la pr\u00E9sente soci\u00E9t\u00E9 ... Les op\u00E9rations de la soci\u00E9t\u00E9 absorb\u00E9e seront consid\u00E9r\u00E9es du point de vue comptable comme accomplies pour le compte de la soci\u00E9t\u00E9 absorbante \u00E0 dater du 1er janvier 2016."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "final_status": "opgeslorpt_door_fusie",
  "subject_company": {
    "kbo": "0543.573.053"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": null,
      "currency": "EUR",
      "after_eur": 1985064325.46,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "onbekend",
      "effective_date": "2016-03-18",
      "evidence_quote": "Que, suite \u00E0 une erreur dans l\u0027acte d\u0027augmentation de capital de la soci\u00E9t\u00E9 priv\u00E9e \u00E0 responsabilit\u00E9 limit\u00E9e UCB BIOPHARMA, re\u00E7u par le notaire Damien HISETTE, soussign\u00E9, le dix-huit mars deux mille seize... il a \u00E9t\u00E9 indiqu\u00E9 qu\u0027apr\u00E8s l\u0027augmentation de capital, le capital social \u00E9tait repr\u00E9sent\u00E9 par dix millions quatre cent cinquante-deux mille cent trente-neuf (10.452.139) parts sociales alors qu\u0027en r\u00E9alit\u00E9 le nombre de parts sociales repr\u00E9sentant le capital social apr\u00E8s l\u0027augmentation s\u0027\u00E9l\u00E8ve \u00E0 dix millions quatre cent quatre-vingt-huit mille cent trente-neuf (10.488.139).",
      "contribution_type": null
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 110676279.18,
      "currency": "EUR",
      "after_eur": 1985064325.46,
      "delta_eur": 110676279.18,
      "before_eur": 1874388046.28,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2016-03-18",
      "evidence_quote": "L\u0027assembl\u00E9e d\u00E9cide d\u0027augmenter le capital \u00E0 concurrence de cent dix millions six cent septante-six mille deux cent septante-neuf euros et dix-huit cents (110.676.279,18 EUR) pour le porter d\u0027un milliard huit-cent septante-quatre millions trois cent quatre-vingt-huit mille quarante-six euros et vingt-huit cents (1.874.388.046,28 EUR) \u00E0 un milliard neuf cent quatre-vingt-cinq millions soixante-quatre miile trois cent vingt-cing euros et quarante-six cents (1.985.064.325,46 EUR) par l\u0027\u00E9mission de cing cent quatre-vingt-quatre mille sept cent soixante et une (584.761) nouvelles parts soc\u00EDales... int\u00E9gralement lib\u00E9r\u00E9es en esp\u00E8ces lors de la souscription.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}

{
  "stage": "proposal",
  "notary": {
    "name": "Jeroen De Schauwer",
    "firm_city": null,
    "firm_name": null,
    "office_city": "Bruxelles",
    "is_associated": false
  },
  "act_meta": {
    "language": "fr",
    "pub_date": "2016-04-05",
    "filing_date": "2016-03-24",
    "act_kind_objet": ""
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2016-03-18",
    "unanimous": null
  },
  "conversion": null,
  "detected_kind": "merger_absorption",
  "report_waiver": null,
  "restructuring": {
    "parties": [
      {
        "kbo": "0543.573.053",
        "name": "UCB BIOPHARMA SPRL",
        "role": "acquiring",
        "address": "All\u00E9e de la Recherche 60, 1070 Bruxelles (Anderlecht)",
        "is_foreign": false,
        "legal_form": "SPRL",
        "is_new_company": false,
        "jurisdiction_country": "BE"
      },
      {
        "kbo": "0644.644.083",
        "name": "UCB BIOPHARMA IRELAND LIMITED",
        "role": "absorbed",
        "address": "Shannon Industrial Estate, Shannon, Co. Clare, Irelande",
        "is_foreign": true,
        "legal_form": "Private company limited by shares",
        "is_new_company": false,
        "jurisdiction_country": "IE"
      }
    ],
    "exchange_ratio": null,
    "legal_articles": [
      "12:7",
      "12:50",
      "12:75"
    ],
    "is_cross_border": true,
    "is_silent_merger": false,
    "balance_basis_date": "2015-12-31",
    "exchange_ratio_text": null,
    "new_shares_issued_n": 0,
    "real_estate_included": false,
    "patrimony_description": "Le patrimoine entier de la soci\u00E9t\u00E9 absorb\u00E9e, notamment ses droits de propri\u00E9t\u00E9 intellectuelle dans le secteur biopharmaceutique, est transf\u00E9r\u00E9 \u00E0 la soci\u00E9t\u00E9 absorbante. Les actifs et passifs sont valoris\u00E9s selon leurs comptes arr\u00EAt\u00E9s au 31 d\u00E9cembre 2015.",
    "equity_transferred_eur": null,
    "accounting_effective_date": "2016-01-01"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Jeroen De Schauwer",
    "org_rep_person_name": null
  },
  "summary_narrative": "Le projet commun de fusion par absorption de UCB BIOPHARMA IRELAND LIMITED par UCB BIOPHARMA SPRL a \u00E9t\u00E9 approuv\u00E9 le 18 mars 2016 par les organes de gestion des deux soci\u00E9t\u00E9s. L\u0027op\u00E9ration, qui est transfrontali\u00E8re, vise \u00E0 transf\u00E9rer l\u0027int\u00E9gralit\u00E9 du patrimoine de la soci\u00E9t\u00E9 irlandaise, notamment ses droits de propri\u00E9t\u00E9 intellectuelle, \u00E0 la soci\u00E9t\u00E9 belge. Les comptes utilis\u00E9s pour d\u00E9finir les conditions de la fusion sont ceux arr\u00EAt\u00E9s au 31 d\u00E9cembre 2015, et les effets comptables sont r\u00E9troactifs au 1er janvier 2016.",
  "co_filed_documents": [
    "Annexe 1 : Statuts de la Soci\u00E9t\u00E9 Absorbante (version fran\u00E7aise)",
    "Annexe 2 : Traduction jur\u00E9e anglaise des statuts de la Soci\u00E9t\u00E9 Absorbante"
  ],
  "detected_real_type": "fusion_proposal",
  "referenced_correction": null,
  "should_reroute_to_category": null
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Anna Sessan Richo",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2016-01-15",
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 268 \u00A72 du Code des Soci\u00E9t\u00E9s, les actionnaires d\u00E9c\u00EDdent \u00E0 l\u0027unanimit\u00E9 de nommer, avec effet imm\u00E9diat, Anna Sessan Richo, All\u00E9e de la Recherche, 60 \u00E0 1070 Bruxelles et Ismail Kola, domicili\u00E9 Rue du Page 14 \u00E0 1050 Bruxelles, en qualit\u00E9 de g\u00E9rants."
    },
    {
      "kind": "director_in",
      "role": "gedelegeerd_bestuurder",
      "person": {
        "rrn": null,
        "name": "Ismail Kola",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2016-01-15",
      "evidence_quote": "Conform\u00E9ment \u00E0 l\u0027article 268 \u00A72 du Code des Soci\u00E9t\u00E9s, les actionnaires d\u00E9c\u00EDdent \u00E0 l\u0027unanimit\u00E9 de nommer, avec effet imm\u00E9diat, Anna Sessan Richo, All\u00E9e de la Recherche, 60 \u00E0 1070 Bruxelles et Ismail Kola, domicili\u00E9 Rue du Page 14 \u00E0 1050 Bruxelles, en qualit\u00E9 de g\u00E9rants."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0543.573.053",
    "name_full": "UCB BIOPHARMA",
    "legal_form": "SPRL"
  }
}